POET Technologies Capital Raise at Premium Masks Twin Storms: Marvell Cancellation and Shareholder Lawsuits

POET raises $400M at a 31% premium despite Marvell termination, class-action threats, and widening losses; signs $500M Lumilens deal but faces heavy dilution.

The narrative surrounding POET Technologies has rarely been more fractured. On one side, the company has secured a $400 million direct placement at a hefty 31% premium to its prior closing price, a vote of confidence from a single institutional investor. On the other, it is grappling with a major customer defection, a wave of impending class-action lawsuits, and a cash-burning business model that makes the fresh capital an urgent necessity rather than a luxury.

The turmoil traces directly to late April, when Marvell Semiconductor abruptly terminated all purchase orders with Celestial AI, a subsidiary POET had recently acquired. Marvell accused POET of improperly disclosing confidential supply information, sending the stock into a freefall of more than 47% in a single session. That collapse has since attracted the attention of several US law firms, which are preparing securities class actions alleging false statements regarding the company’s tax status. Investors have until June 29 to name a lead plaintiff.

Against this backdrop, POET announced a direct placement of shares and warrants at a combined $21.00 per unit, well above the $15.97 closing price just before the announcement. The deal, expected to close around May 18, will hand the company roughly $400 million in gross proceeds. Management intends to channel the funds into production capacity expansion, strategic acquisitions, and increased research and development spending. The structure – one common share plus one warrant per unit – means existing shareholders face significant dilution, a fear that helped drive the stock down 22% on the Friday following the news.

A bright spot emerged midweek when POET disclosed a five-year supply agreement with Lumilens for optical components. The initial order is valued at $50 million, with the total potential volume reaching $500 million over the contract’s life. Lumilens will also receive extensive stock purchase rights, aligning the two companies in a push to scale production of optical chips for the booming AI data-center market. Yet even this milestone arrives with caveats: POET's quarterly revenue stood at just over $500,000 in the first quarter of 2026, while its net loss widened to $12.3 million, narrowly missing analyst estimates.

Operationally, the company is in the midst of an overhaul. CFO Thomas Mika, who has held the role for a decade, will retire later this year, and a successor is being sought. Meanwhile, the board has proposed relocating the corporate headquarters to the United States, a move designed to prevent POET from being classified as a passive foreign investment company (PFIC) – a classification that carries adverse tax consequences for US investors. The proposal will be put to a shareholder vote at the annual meeting on June 26.

Short-term trading dynamics have added another layer of instability. A newly launched leveraged ETF from Defiance ETFs, ticker POEL, is explicitly designed to amplify daily moves in POET’s stock, mechanically exacerbating the already violent intraday swings. The stock, which briefly rallied to near $21 in mid-May before retreating to $15.97, remains a high-wire act for momentum traders.

With operating cash burn running close to $9 million and R&D expenditure at $4.5 million, POET is racing to transition from a development-stage technology firm to a revenue-generating manufacturer. The $400 million lifeline, if it clears without further legal or operational shocks, provides the necessary runway. But between the Marvell fallout and the June 29 class-action deadline, the next few weeks will be the truest test of whether the market’s optimism can outlast its anxieties.